Clinical trial expected to be initiated shortly after NMPA approval of the IND Sesen Bio to receive $3M milestone payment upon IND approval CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 13, 2021-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for
